Wells Fargo & Company Keros Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 11,519 shares of KROS stock, worth $650,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,519
Previous 9,309
23.74%
Holding current value
$650,247
Previous $616,000
14.61%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding KROS
# of Institutions
157Shares Held
27.1MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$142 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$99.2 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$90.3 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$86.1 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$71.6 Million1.4% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.45B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...